Stay updated on Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.

Latest updates to the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page
- Check4 days agoChange DetectedThe page revision was updated from v3.4.0 to v3.4.1, with no visible content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoChange DetectedAdded a glossary display option and new labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and introduced a 'No FEAR Act Data' notice. The older items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.2%

- Check18 days agoChange DetectedDeleted the Statistical Analysis Plan (2018-02-02, 2.35MB) and the Study Protocol (2020-06-08, 1.12MB) from the study documents.SummaryDifference19%

- Check25 days agoChange DetectedThe page shows a minor site revision update from v3.3.3 to v3.3.4 (UI changes) with no impact on study content or functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded a Locations section with Attica as a study site and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check76 days agoChange DetectedPublications section wording was updated to clarify automatic population from PubMed (and related notifications), and the revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.